A New Weight-Loss Pill Successfully Fights Against Obesity And Overweight


The fight with excess weight and obesity is a hard one and few solutions besides the bariatric surgery have been able to win it. A weight loss pill has been hailed as a “holy grail” in the hard battle against obesity after a significant study showed that it did not increase the risk of severe heart issues.

Researchers say that lorcaserin is the very first weight-loss drug that is deemed safe for heart health with long-term use. Taken twice a day, the drug is an appetite suppressant which works by stimulating brain chemicals in order to induce a feeling of fullness.

A US new study analyzed 12,000 people who were obese or overweight. They were given the pills or a placebo, and the results showed that the ones who took the drug lost about 9lbs (4kg) in a month.

The holy-grail of weight-loss medicine may have been discovered 

More analysis showed no significant differences in tests for heart valve damage. Tam Fry, of Britain’s National Obesity Forum, said that the drug could be the “holy grail” of weight-loss medicine.

“I think it is the thing everybody has been looking for,” he said.

“I think there will be several holy grails, but this is a holy grail and one which has been certainly at the back of the mind of a lot of specialists for a long time. But all of the other things apply – lifestyle change has got to be root and branch part of this,” Fry stated.

Prof. Jason Halford who is an obesity expert at the University of Liverpool told the Daily Telegraph newspaper that the drug’s availability in the UK would depend on whether the National Health Service regulators approve it.

“We don’t have any appetite suppressants available on the NHS. We have a great massive gap between lifestyle modification and surgery,” he said.

“At the moment you either get support and advice, or you get to surgery – there is nothing in between. This could be widely prescribed if it is approved by Nice (the National Institute of Health and Care Excellence) in the UK.”


Recommended For You

Leave a Reply

Your email address will not be published. Required fields are marked *